CoChat

The exostosin glycosyltransferase 1/STAT3 axis is a driver of breast cancer aggressiveness

Open access
Solaimuthu, Balakrishnan, Khatib, Anees, Tanna, Mayur, Karmi, Abdelrahman, Hayashi, Arata, Abu Rmaileh, Areej, Lichtenstein, Michal, Takoe, Suranjana, Jolly, Mohit Kumar, Shaul, Yoav David · 2024 · Proceedings of the National Academy of Sciences

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Abstract

The epithelial–mesenchymal transition (EMT) program is crucial for transforming carcinoma cells into a partially mesenchymal state, enhancing their chemoresistance, migration, and metastasis. This shift in cell state is tightly regulated by cellular mechanisms that are not yet fully characterized. One intriguing EMT aspect is the rewiring of the proteoglycan landscape, particularly the induction of heparan sulfate proteoglycan (HSPG) biosynthesis. This proteoglycan functions as a co-receptor that accelerates cancer-associated signaling pathways through its negatively-charged residues. However, the precise mechanisms through which EMT governs HSPG biosynthesis and its role in cancer cell plasticity remain elusive. Here, we identified exostosin glycosyltransferase 1 (EXT1), a central enzyme in HSPG biosynthesis, to be selectively upregulated in aggressive tumor subtypes and cancer cell lines, and to function as a key player in breast cancer aggressiveness. Notably, ectopic expression of EXT1 in epithelial cells is sufficient to induce HSPG levels and the expression of known mesenchymal markers, subsequently enhancing EMT features, including cell migration, invasion, and tumor formation. Additionally, EXT1 loss in MDA-MB-231 cells inhibits their aggressiveness-associated traits such as migration, chemoresistance, tumor formation, and metastasis. Our findings reveal that EXT1, through its role in HSPG biosynthesis, governs signal transducer and activator of transcription 3 (STAT3) signaling, a known regulator of cancer cell aggressiveness. Collectively, we present the EXT1/HSPG/STAT3 axis as a central regulator of cancer cell plasticity that directly links proteoglycan synthesis to oncogenic signaling pathways.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.2316733121

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. EXT1 expression and heparan sulfate levels correlate with breast cancer aggressiveness. (A) HSPG levels are upregulated in mesenchymal cell lines. The indicated breast cancer–derived cell lines were subjected to FACS analysis using heparan sulfate-specific 10E4 antibody (Left). The HS median fluorescence intensity was calculated for the epithelial (E) and mesenchymal cell lines (M) (Right); each bar represents the mean ± SD for n = 3. The P-value was determined by Student’s t test. (B) HSPG levels are upregulated in NAMEC vs. HMLE cells. NAMEC is an HMLE-derived cell line that spontaneously acquired the mesenchymal state. The indicated HMLE and NAMEC cell lines were subjected to FACS analysis using the indicated 10E4 antibody (Left). The HS median fluorescence intensity was calculated for the epithelial and mesenchymal cell lines (Right); each bar represents the mean ± SD for n = 5. The P-value was determined by Student’s t test, (C) EXT1 demonstrated elevated expression in mesenchymal cells. Cancer cell lines were divided into epithelial (n = 378 cell lines) and mesenchymal (n = 150 cell lines) groups based on the expression of known mesenchymal markers. The expression of the 10 HS biosynthesis genes was compared with the mean expression in each group. The regression line is presented as a dashed line. (D) The EXT1 protein level is upregulated in mesenchymal breast cancer cell lines. Cells were lysed and subjected to immunoblotting using the indicated antibodies. (E) EXT1 expression is upregulated during the EMT program. HMLE-Twist-ER cells were treated with 4-hydroxytamoxifen (OHT) to induce EMT for 15 d. The cells were collected every 3 d, then lysed and subjected to immunoblotting using the indicated antibodies. N-NAMEC cells. (F) TGFβ1 induces EXT1 expression. HCC1806 cells were treated with 5 ng/mL of TGFβ1 to induce the EMT program for 15 d. Cells were collected and subjected to immunoblotting on each indicated day using the indicated antibodies. (G) EXT1 expression in breast cancer patients correlates with the hallmark of EMT. Breast cancer patients’ gene expression data were generated by the TCGA (PanCancer Atlas project) and analyzed using the cBioPortal web tool (https://www.cbioportal.org). In these samples, the expression of EXT1 was compared to the whole transcriptome (~20,000 genes). The genes were then ranked based on the obtained Spearman’s rank correlation coefficient followed and subjected to gene set enrichment analysis (GSEA). GSEA computed the normalized enrichment score (NES) and false discovery rate (FDR) values. (H) EXT1 expression is elevated in the aggressive breast cancer subtypes. Breast cancer samples were divided into groups based on high and low EXT1 expression (one SD above or below the mean). For each group, the percentage of breast cancer subtypes is color-coded. The breast cancer data was obtained from the METABRIC databases. The cBioPortal calculated the P-values. Lum = luminal. (I) A table reporting the number of human breast cancer samples with “weak,” “moderate,” and “strong” EXT1 staining from triple-negative breast cancer (TNBC) or HER2+, PR-, and ER- (HER2+). Representative staining intensities are shown in images. Magnification, 20×, *P = 0.03 as determined by Fischer’s exact test. (J) EXT1 expression is associated with overall survival (OE), relapse-free survival (RFS), and DM-free survival (DMFS). Kaplan–Meier survival plots for patients with breast cancer were divided into high EXT1 expression [“high” (red)] and low [“low” (black)]. The numbers in parentheses indicate the total number of patients. These plots were generated by the Kaplan–Meier plotter website. The EXT1 (201995_at Affymetrix ID symbol) was used for all the analyses. The number of patients in each study is indicated in parentheses. The hazard ratio (HR) and the log-rank P-value (p) were determined by the analysis tool.
Fig. 1. EXT1 expression and heparan sulfate levels correlate with breast cancer aggressiveness. (A) HSPG levels are upregulated in mesenchymal cell lines. The indicated breast cancer–derived cell lines were subjected to FACS analysis using heparan sulfate-specific 10E4 antibody (Left). The HS median fluorescence intensity was calculated for the epithelial (E) and mesenchymal cell lines (M) (Right); each bar represents the mean ± SD for n = 3. The P-value was determined by Student’s t test. (B) HSPG levels are upregulated in NAMEC vs. HMLE cells. NAMEC is an HMLE-derived cell line that spontaneously acquired the mesenchymal state. The indicated HMLE and NAMEC cell lines were subjected to FACS analysis using the indicated 10E4 antibody (Left). The HS median fluorescence intensity was calculated for the epithelial and mesenchymal cell lines (Right); each bar represents the mean ± SD for n = 5. The P-value was determined by Student’s t test, (C) EXT1 demonstrated elevated expression in mesenchymal cells. Cancer cell lines were divided into epithelial (n = 378 cell lines) and mesenchymal (n = 150 cell lines) groups based on the expression of known mesenchymal markers. The expression of the 10 HS biosynthesis genes was compared with the mean expression in each group. The regression line is presented as a dashed line. (D) The EXT1 protein level is upregulated in mesenchymal breast cancer cell lines. Cells were lysed and subjected to immunoblotting using the indicated antibodies. (E) EXT1 expression is upregulated during the EMT program. HMLE-Twist-ER cells were treated with 4-hydroxytamoxifen (OHT) to induce EMT for 15 d. The cells were collected every 3 d, then lysed and subjected to immunoblotting using the indicated antibodies. N-NAMEC cells. (F) TGFβ1 induces EXT1 expression. HCC1806 cells were treated with 5 ng/mL of TGFβ1 to induce the EMT program for 15 d. Cells were collected and subjected to immunoblotting on each indicated day using the indicated antibodies. (G) EXT1 expression in breast cancer patients correlates with the hallmark of EMT. Breast cancer patients’ gene expression data were generated by the TCGA (PanCancer Atlas project) and analyzed using the cBioPortal web tool (https://www.cbioportal.org). In these samples, the expression of EXT1 was compared to the whole transcriptome (~20,000 genes). The genes were then ranked based on the obtained Spearman’s rank correlation coefficient followed and subjected to gene set enrichment analysis (GSEA). GSEA computed the normalized enrichment score (NES) and false discovery rate (FDR) values. (H) EXT1 expression is elevated in the aggressive breast cancer subtypes. Breast cancer samples were divided into groups based on high and low EXT1 expression (one SD above or below the mean). For each group, the percentage of breast cancer subtypes is color-coded. The breast cancer data was obtained from the METABRIC databases. The cBioPortal calculated the P-values. Lum = luminal. (I) A table reporting the number of human breast cancer samples with “weak,” “moderate,” and “strong” EXT1 staining from triple-negative breast cancer (TNBC) or HER2+, PR-, and ER- (HER2+). Representative staining intensities are shown in images. Magnification, 20×, *P = 0.03 as determined by Fischer’s exact test. (J) EXT1 expression is associated with overall survival (OE), relapse-free survival (RFS), and DM-free survival (DMFS). Kaplan–Meier survival plots for patients with breast cancer were divided into high EXT1 expression [“high” (red)] and low [“low” (black)]. The numbers in parentheses indicate the total number of patients. These plots were generated by the Kaplan–Meier plotter website. The EXT1 (201995_at Affymetrix ID symbol) was used for all the analyses. The number of patients in each study is indicated in parentheses. The hazard ratio (HR) and the log-rank P-value (p) were determined by the analysis tool.CC BY-NC-ND · PubMed Central
Fig. 2. EXT1 is sufficient to induce HSPG synthesis and the EMT program. (A) Immunoblots representing WT (VC), EXT1 overexpression (EXT1-FLAG), and the catalytically inactive mutant (EXT1-D164A-FLAG) in MCF-7 (Upper) and MDA-MB-468 (Lower) cancer cell lines. Cells were lysed and subjected to immunoblotting using the indicated antibodies. VC-vector control. (B) EXT1 activity is essential for HSPG formation. The same cells as (A) were subjected to FACS analysis using the indicated 10E4 antibody (Left). The HS median fluorescence intensity was calculated for each cell line (Right); each bar represents the mean ± SD for n = 3. P = 0.0002, ****P < 0.0001 was determined by Student’s t test. (C) EXT1 induces the overexpression of the mesenchymal gene set. MCF-7 cells expressing vector control (VC) WT and EXT1-FLAG were subjected to comparative RNA-Seq analysis. For each gene, the ratio between WT and EXT1-FLAG was calculated, ranked, and then subjected to gene set enrichment analysis (GSEA). GSEA computed the normalized enrichment score (NES) and false discovery rate (FDR) values. (D) Selected EMT markers are upregulated in EXT1-FLAG expression in both MCF-7 and MDA-MB-468 breast cancer cell lines. Immunoblots representing WT (VC), EXT1 overexpression (EXT1-FLAG), and the catalytically inactive mutant (EXT1-D164A-FLAG) in MCF-7 (Left) and MDA-MB-468 (Right) cancer cell lines. Cells were lysed and subjected to immunoblotting using the indicated antibodies. VC-vector control. (E) EXT1 overexpression in MCF-7 affects SLUG and E-cadherin expression. EXT1-WT and EXT1-FLAG MCF-7 cells were subjected to immunofluorescence imaging using the indicated antibodies. ECAD = E-cadherin. (Scale bar: 10 μm.) (F) EXT1 overexpression in MDA-MB-468 affects E-cadherin (ECAD), N-cadherin (NCAD), and vimentin (VIM) expression. EXT1-WT and EXT1-FLAG MDA-MB-468 cells were subjected to immunofluorescence imaging using the indicated antibodies. (Scale bar: 10 μm.)
Fig. 2. EXT1 is sufficient to induce HSPG synthesis and the EMT program. (A) Immunoblots representing WT (VC), EXT1 overexpression (EXT1-FLAG), and the catalytically inactive mutant (EXT1-D164A-FLAG) in MCF-7 (Upper) and MDA-MB-468 (Lower) cancer cell lines. Cells were lysed and subjected to immunoblotting using the indicated antibodies. VC-vector control. (B) EXT1 activity is essential for HSPG formation. The same cells as (A) were subjected to FACS analysis using the indicated 10E4 antibody (Left). The HS median fluorescence intensity was calculated for each cell line (Right); each bar represents the mean ± SD for n = 3. P = 0.0002, ****P < 0.0001 was determined by Student’s t test. (C) EXT1 induces the overexpression of the mesenchymal gene set. MCF-7 cells expressing vector control (VC) WT and EXT1-FLAG were subjected to comparative RNA-Seq analysis. For each gene, the ratio between WT and EXT1-FLAG was calculated, ranked, and then subjected to gene set enrichment analysis (GSEA). GSEA computed the normalized enrichment score (NES) and false discovery rate (FDR) values. (D) Selected EMT markers are upregulated in EXT1-FLAG expression in both MCF-7 and MDA-MB-468 breast cancer cell lines. Immunoblots representing WT (VC), EXT1 overexpression (EXT1-FLAG), and the catalytically inactive mutant (EXT1-D164A-FLAG) in MCF-7 (Left) and MDA-MB-468 (Right) cancer cell lines. Cells were lysed and subjected to immunoblotting using the indicated antibodies. VC-vector control. (E) EXT1 overexpression in MCF-7 affects SLUG and E-cadherin expression. EXT1-WT and EXT1-FLAG MCF-7 cells were subjected to immunofluorescence imaging using the indicated antibodies. ECAD = E-cadherin. (Scale bar: 10 μm.) (F) EXT1 overexpression in MDA-MB-468 affects E-cadherin (ECAD), N-cadherin (NCAD), and vimentin (VIM) expression. EXT1-WT and EXT1-FLAG MDA-MB-468 cells were subjected to immunofluorescence imaging using the indicated antibodies. (Scale bar: 10 μm.)CC BY-NC-ND · PubMed Central
Fig. 3. EXT1 overexpression increases the epithelial cell migratory capabilities. (A) Real-time quantification of relative wound density for the indicated WT, EXT1-FLAG, and EXT1-D164A-FLAG cells. The cells were monitored for the indicated time. Each bar represents the mean ± SD for n = 8. The P-value was determined by Student’s t test. (B) EXT1 overexpression induces MCF-7 and MDA-MB-468 cell migration. The migratory capability of the different samples was determined in a Boyden chamber-based transwell migration assay. Quantification of data is reported as the number of migrated cells per 25,000 seeded cells; each bar represents the mean ± SD for n = 3. **P = 0.0013 (Left) P = 0.0052 (Right), ***P = 0.0008, ****P < 0.0001 was determined by Student’s t test. (C) EXT1 overexpression induces MCF-7 and MDA-MB-468 cell invasion. The indicated cells were infected and treated as in (B), and the number of the Matrigel-invading cells was measured. Quantification of data is reported as the number of invading cells per 20,000 seeded cells; each value represents the mean ± SD for n = 3. **P = 0.002, ***P = 0.0001, ****P < 0.0001 was determined by Student’s t test. (D) EXT1 expression increases the tumor growth kinetics. MDA-MB-468 cells were injected into the mammary fat pad in SCID/NOD mice. At the indicated week, the tumor growth kinetics of WT MDA-MB-468 (VC), EXT1-FLAG, and EXT1-D164A-FLAG overexpressing cells in NOD-SCID mice were determined every 2 wk by the bioluminescence machine. (E) Quantification of the bioluminescence images. Each sphere represents the bioluminescence in a mouse n = 8. **P = 0.003, ***P = 0.0003 was determined by the Mann-Whitney U test. (F) Representative images of NOD-SCID mice after 12 wk post-injection with MDA-MB-468 cells expressing VC, EXT-FLAG, or EXT1-D164A-FLAG were captured using bioluminescence. The color bar represents the intensity of luminescence. (G) The tumors were harvested from the mice, weighed, and presented as a graph. *P = 0.023 (Left) P = 0.037 (Right) was determined by Student’s t test.
Fig. 3. EXT1 overexpression increases the epithelial cell migratory capabilities. (A) Real-time quantification of relative wound density for the indicated WT, EXT1-FLAG, and EXT1-D164A-FLAG cells. The cells were monitored for the indicated time. Each bar represents the mean ± SD for n = 8. The P-value was determined by Student’s t test. (B) EXT1 overexpression induces MCF-7 and MDA-MB-468 cell migration. The migratory capability of the different samples was determined in a Boyden chamber-based transwell migration assay. Quantification of data is reported as the number of migrated cells per 25,000 seeded cells; each bar represents the mean ± SD for n = 3. **P = 0.0013 (Left) P = 0.0052 (Right), ***P = 0.0008, ****P < 0.0001 was determined by Student’s t test. (C) EXT1 overexpression induces MCF-7 and MDA-MB-468 cell invasion. The indicated cells were infected and treated as in (B), and the number of the Matrigel-invading cells was measured. Quantification of data is reported as the number of invading cells per 20,000 seeded cells; each value represents the mean ± SD for n = 3. **P = 0.002, ***P = 0.0001, ****P < 0.0001 was determined by Student’s t test. (D) EXT1 expression increases the tumor growth kinetics. MDA-MB-468 cells were injected into the mammary fat pad in SCID/NOD mice. At the indicated week, the tumor growth kinetics of WT MDA-MB-468 (VC), EXT1-FLAG, and EXT1-D164A-FLAG overexpressing cells in NOD-SCID mice were determined every 2 wk by the bioluminescence machine. (E) Quantification of the bioluminescence images. Each sphere represents the bioluminescence in a mouse n = 8. **P = 0.003, ***P = 0.0003 was determined by the Mann-Whitney U test. (F) Representative images of NOD-SCID mice after 12 wk post-injection with MDA-MB-468 cells expressing VC, EXT-FLAG, or EXT1-D164A-FLAG were captured using bioluminescence. The color bar represents the intensity of luminescence. (G) The tumors were harvested from the mice, weighed, and presented as a graph. *P = 0.023 (Left) P = 0.037 (Right) was determined by Student’s t test.CC BY-NC-ND · PubMed Central
Fig. 4. EXT1 expression regulates breast cancer aggressiveness. (A) Immunoblot representing EXT1 knockout (EXT1-KO) in MDA-MB-231. EXT1 knockout was generated using the CRISPR-Cas9 system, followed by separating the cells into single clones. FLAG-tagged EXT1 (EXT1-FLAG) and catalytically inactive mutant (EXT1-D164A-FLAG) were reintroduced into EXT1-KO cells. Cells were lysed and subjected to immunoblotting using the indicated antibodies. (B) Silencing of EXT1 expression in MDA-MB-231 cells using the CRISPR-Cas9 system induces epithelial-like characteristics. (Scale bar: 100 μm.) (C) EXT1 activity is essential for HSPG formation. The same cells as (A) were subjected to FACS analysis using the indicated 10E4 antibody (Left). The HS median fluorescence intensity was calculated for each sample (Right). Each bar represents the mean ± SD for n = 3. ****P < 0.0001 was determined by Student’s t test. (D) The same cells as (A) were subjected to real-time quantification of relative wound density. The cells were monitored for the indicated time. Each bar represents the mean ± SD for n = 8. ****P < 0.0001 was determined by Student’s t test. (E) EXT1 loss inhibits cell migration and invasion in breast cancer cells. The same cells as (A) were subjected to Boyden chamber-based transwell migration assay (Left). Quantification of data is reported as the number of migrated cells per 20,000 seeded cells; each bar represents the mean ± SD for n = 3. The P-value was determined by Student’s t test. The same cells as (A) were subjected to a Matrigel-based invasion assay (Right). Quantification of data is reported as the number of migrated cells per 25,000 seeded cells. Each value represents the mean ± SD for n = 3. *P = 0.01, **P = 0.002, ***P = 0.0008 was determined by Student’s t test. (F) EXT1 loss induces drug sensitivity. EXT1-WT and EXT1-KO cells were treated with increasing concentrations of 5-fluorouracil (5-FU, Top), cyclophosphamide (Middle), and gemcitabine (Bottom). The cells were treated with the drugs for 48 h, then the number of cells was measured using CellTiter Glo. For each time point, n = 3.
Fig. 4. EXT1 expression regulates breast cancer aggressiveness. (A) Immunoblot representing EXT1 knockout (EXT1-KO) in MDA-MB-231. EXT1 knockout was generated using the CRISPR-Cas9 system, followed by separating the cells into single clones. FLAG-tagged EXT1 (EXT1-FLAG) and catalytically inactive mutant (EXT1-D164A-FLAG) were reintroduced into EXT1-KO cells. Cells were lysed and subjected to immunoblotting using the indicated antibodies. (B) Silencing of EXT1 expression in MDA-MB-231 cells using the CRISPR-Cas9 system induces epithelial-like characteristics. (Scale bar: 100 μm.) (C) EXT1 activity is essential for HSPG formation. The same cells as (A) were subjected to FACS analysis using the indicated 10E4 antibody (Left). The HS median fluorescence intensity was calculated for each sample (Right). Each bar represents the mean ± SD for n = 3. ****P < 0.0001 was determined by Student’s t test. (D) The same cells as (A) were subjected to real-time quantification of relative wound density. The cells were monitored for the indicated time. Each bar represents the mean ± SD for n = 8. ****P < 0.0001 was determined by Student’s t test. (E) EXT1 loss inhibits cell migration and invasion in breast cancer cells. The same cells as (A) were subjected to Boyden chamber-based transwell migration assay (Left). Quantification of data is reported as the number of migrated cells per 20,000 seeded cells; each bar represents the mean ± SD for n = 3. The P-value was determined by Student’s t test. The same cells as (A) were subjected to a Matrigel-based invasion assay (Right). Quantification of data is reported as the number of migrated cells per 25,000 seeded cells. Each value represents the mean ± SD for n = 3. *P = 0.01, **P = 0.002, ***P = 0.0008 was determined by Student’s t test. (F) EXT1 loss induces drug sensitivity. EXT1-WT and EXT1-KO cells were treated with increasing concentrations of 5-fluorouracil (5-FU, Top), cyclophosphamide (Middle), and gemcitabine (Bottom). The cells were treated with the drugs for 48 h, then the number of cells was measured using CellTiter Glo. For each time point, n = 3.CC BY-NC-ND · PubMed Central
Fig. 5. EXT1 loss affects tumor formation and metastasis in mice. (A) The kinetics effect of EXT1 loss on tumor growth was determined by the bioluminescence machine. In vivo, tumor growth kinetics of WT MDA-MB-231 (EXT1-WT) and EXT1-KO cells were determined every 2 wk in NOD-SCID mice **P = 0.004, the P-value was determined by Student’s t test, n = 9. (B) Representative images of mice after 4 wk post-injection. The images were captured using bioluminescence. The color bar represents the intensity of luminescence. (C) The tumors were harvested from the mice, weighed, and presented as a graph. ***P = 0.0005 was determined by Student’s t test, n = 9. (D) EXT1 loss inhibits metastasis formation. Female NOD-SCID mice were injected with EXT1-WT or EXT1-KO MDA-MB-231 cells. The table reports the number of mice with positive GFP colonies in their lung out of the total number of mice. *P = 0.01 as determined by Fischer’s exact test. (E) EXT1 loss reduces the number of lung metastases. Representative lungs were obtained from WT- and EXT1-KO-injected mice as described in (A). Brightfield images of the lung (Left). Fluorescence images of GFP-labeled colonies (Right). Arrows indicate the detected GFP-expressing metastases. (Bar: 5 mm.) (F) EXT1-WT, EXT1-KO, and EXT1-KO+EXT1-FLAG MDA-MB-231 cells were injected into the mouse tail vein for 4 wk. Representative lungs were obtained from the injected mice. Brightfield images of the lung (Left). Fluorescence images of GFP-labeled colonies (Middle). Arrows indicate the detected GFP-expressing metastases. (Bar: 5 mm.) The GFP-labeled colonies in the lung were quantified (Right). *P = 0.01, ***P = 0.0003 was determined by the Mann-Whitney U test. Each bar represents the mean ± SD, EXT1-WT n = 8, other samples n = 7.
Fig. 5. EXT1 loss affects tumor formation and metastasis in mice. (A) The kinetics effect of EXT1 loss on tumor growth was determined by the bioluminescence machine. In vivo, tumor growth kinetics of WT MDA-MB-231 (EXT1-WT) and EXT1-KO cells were determined every 2 wk in NOD-SCID mice **P = 0.004, the P-value was determined by Student’s t test, n = 9. (B) Representative images of mice after 4 wk post-injection. The images were captured using bioluminescence. The color bar represents the intensity of luminescence. (C) The tumors were harvested from the mice, weighed, and presented as a graph. ***P = 0.0005 was determined by Student’s t test, n = 9. (D) EXT1 loss inhibits metastasis formation. Female NOD-SCID mice were injected with EXT1-WT or EXT1-KO MDA-MB-231 cells. The table reports the number of mice with positive GFP colonies in their lung out of the total number of mice. *P = 0.01 as determined by Fischer’s exact test. (E) EXT1 loss reduces the number of lung metastases. Representative lungs were obtained from WT- and EXT1-KO-injected mice as described in (A). Brightfield images of the lung (Left). Fluorescence images of GFP-labeled colonies (Right). Arrows indicate the detected GFP-expressing metastases. (Bar: 5 mm.) (F) EXT1-WT, EXT1-KO, and EXT1-KO+EXT1-FLAG MDA-MB-231 cells were injected into the mouse tail vein for 4 wk. Representative lungs were obtained from the injected mice. Brightfield images of the lung (Left). Fluorescence images of GFP-labeled colonies (Middle). Arrows indicate the detected GFP-expressing metastases. (Bar: 5 mm.) The GFP-labeled colonies in the lung were quantified (Right). *P = 0.01, ***P = 0.0003 was determined by the Mann-Whitney U test. Each bar represents the mean ± SD, EXT1-WT n = 8, other samples n = 7.CC BY-NC-ND · PubMed Central
Fig. 6. EXT1 loss impairs STAT3 signaling. (A) EXT1 loss reduces the gene expression pattern for “hallmark IL-6/JAK/STAT3 signaling.” MDA-MB-231 WT cells and EXT1-KO-1 were subjected to CEL-Seq analysis. The expression ratio of all genes was calculated and ranked based on the relative expression in EXT1-WT and EXT1-KO. The samples were subjected to GSEA. The FDR q-value was computed by GSEA. (B) IL-6 level is reduced in EXT1-KO cells growth media. After 36 h, cell growth media was collected from each indicated sample, and the IL-6 level was measured using a specific ELISA kit. ****P < 0.0001 was determined by Student’s t test, n = 3. (C) STAT3 phosphorylation correlates with EXT1 expression. Immunoblots representing WT MDA-MB-231 expressing VC, EXT1 knockout (EXT1-KO), and overexpression of the full-length variant (EXT1-FLAG) or the catalytically inactive mutant (EXT1-D164A-FLAG) in the KO background. Cells were lysed and subjected to immunoblotting using the indicated antibodies. (D) EXT1 overexpression in epithelial MCF-7 and MDA-MB-468 cell lines induces STAT3 signaling. Cells expressing vector control (VC) and EXT1-FLAG were lysed and subjected to immunoblotting using the indicated antibodies. (E) Tumors generated from MDA-MB-231 cells that lack EXT1 expression (EXT1-KO) demonstrated reduced STAT3 phosphorylation levels. Three representative tumors originating from WT or EXT1-KO cells were lysed and subjected to immunoblotting using the indicated antibodies. (F) Tumors generated from MDA-MB-468 cell ectopically expressing EXT1-FLAG cells demonstrated elevated STAT3 phosphorylation. Three representative tumors originating from vector control (VC), EXT1-FLAG, or EXT1-D164A-FLAG cells were lysed and subjected to immunoblotting using the indicated antibodies. (G) Loss of EXT1 expression results in STAT3 signaling inhibition. EXT1-WT and EXT1-KO cells were starved with 0% FBS medium for 16 h and treated with 0 and 50 µL of media from HEK-293 cells generating Hyper IL-6 for 1 h. Cells were subjected to immunoblot using the indicated antibodies. (H) CA-STAT3 induces EMT marker expression in MDA-MB-231 cells. RNA was isolated from WT, EXT1-KO, and EXT1-KO + CA-STAT3 cells, and the relative mRNA expression level of the indicated genes was determined by qRT-PCR. Each value represents the mean ± SD for n = 3. (I) Constitutively activated STAT3 (CA-STAT3) improves the migration of EXT1-KO cells. The migratory capability of the different samples was determined using a Boyden chamber-based transwell assay. Quantification of data is reported as the number of migrated cells per 20,000 seeded cells. Each bar represents the mean ± SD for n = 3. ***P = 0.0001 was determined by Student’s t test. (J) Ruxolitinib (RUXO) inhibits EXT1-dependent migration. The indicated cells were subjected to a Boyden chamber-based transwell migration assay. Quantification of data is reported as the number of migrated cells per 20,000 seeded cells; each bar represents the mean ± SD for n = 3. ***P = 0.0002, ****P < 0.0001 was determined by Student’s t test. (K) A schematic representation of the EXT1/HSPG/STAT3 axis in driving cancer cell aggressiveness.
Fig. 6. EXT1 loss impairs STAT3 signaling. (A) EXT1 loss reduces the gene expression pattern for “hallmark IL-6/JAK/STAT3 signaling.” MDA-MB-231 WT cells and EXT1-KO-1 were subjected to CEL-Seq analysis. The expression ratio of all genes was calculated and ranked based on the relative expression in EXT1-WT and EXT1-KO. The samples were subjected to GSEA. The FDR q-value was computed by GSEA. (B) IL-6 level is reduced in EXT1-KO cells growth media. After 36 h, cell growth media was collected from each indicated sample, and the IL-6 level was measured using a specific ELISA kit. ****P < 0.0001 was determined by Student’s t test, n = 3. (C) STAT3 phosphorylation correlates with EXT1 expression. Immunoblots representing WT MDA-MB-231 expressing VC, EXT1 knockout (EXT1-KO), and overexpression of the full-length variant (EXT1-FLAG) or the catalytically inactive mutant (EXT1-D164A-FLAG) in the KO background. Cells were lysed and subjected to immunoblotting using the indicated antibodies. (D) EXT1 overexpression in epithelial MCF-7 and MDA-MB-468 cell lines induces STAT3 signaling. Cells expressing vector control (VC) and EXT1-FLAG were lysed and subjected to immunoblotting using the indicated antibodies. (E) Tumors generated from MDA-MB-231 cells that lack EXT1 expression (EXT1-KO) demonstrated reduced STAT3 phosphorylation levels. Three representative tumors originating from WT or EXT1-KO cells were lysed and subjected to immunoblotting using the indicated antibodies. (F) Tumors generated from MDA-MB-468 cell ectopically expressing EXT1-FLAG cells demonstrated elevated STAT3 phosphorylation. Three representative tumors originating from vector control (VC), EXT1-FLAG, or EXT1-D164A-FLAG cells were lysed and subjected to immunoblotting using the indicated antibodies. (G) Loss of EXT1 expression results in STAT3 signaling inhibition. EXT1-WT and EXT1-KO cells were starved with 0% FBS medium for 16 h and treated with 0 and 50 µL of media from HEK-293 cells generating Hyper IL-6 for 1 h. Cells were subjected to immunoblot using the indicated antibodies. (H) CA-STAT3 induces EMT marker expression in MDA-MB-231 cells. RNA was isolated from WT, EXT1-KO, and EXT1-KO + CA-STAT3 cells, and the relative mRNA expression level of the indicated genes was determined by qRT-PCR. Each value represents the mean ± SD for n = 3. (I) Constitutively activated STAT3 (CA-STAT3) improves the migration of EXT1-KO cells. The migratory capability of the different samples was determined using a Boyden chamber-based transwell assay. Quantification of data is reported as the number of migrated cells per 20,000 seeded cells. Each bar represents the mean ± SD for n = 3. ***P = 0.0001 was determined by Student’s t test. (J) Ruxolitinib (RUXO) inhibits EXT1-dependent migration. The indicated cells were subjected to a Boyden chamber-based transwell migration assay. Quantification of data is reported as the number of migrated cells per 20,000 seeded cells; each bar represents the mean ± SD for n = 3. ***P = 0.0002, ****P < 0.0001 was determined by Student’s t test. (K) A schematic representation of the EXT1/HSPG/STAT3 axis in driving cancer cell aggressiveness.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Cited by

See all 8

Metadata

Authors
Solaimuthu, B., Khatib, A., Tanna, M., Karmi, A., Hayashi, A., Abu Rmaileh, A., Lichtenstein, M., Takoe, S., Jolly, M. K., & Shaul, Y. D.
Affiliations
  • Hebrew University of Jerusalem (IL)
  • Department of Biochemistry and Molecular Biology, The Institute for Medical Research Israel-Canada, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112001, Israel
  • Indian Institute of Science Education and Research Berhampur (IN)
  • Indian Institute of Science Bangalore (IN)
Corresponding author
Shaul, Yoav David
Venue
Proceedings of the National Academy of Sciences
Published
2024-01-12
Volume
121
Issue
3
Pages
e2316733121-e2316733121
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W4390819295
Cited by
8
References
66
Citations by year
2026: 1 · 2025: 2 · 2024: 5
FWCI
1.81
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by-nc-nd)
Funders
  • Israel Science Foundation (299/21, 1816/16)
  • Mizutani Foundation for Glycoscience (220087)
  • HUJI | Lady Davis Fellowship Trust, Hebrew University of Jerusalem (0)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
EXT1, STAT3 signaling, epithelial-mesenchymal transition, breast cancer aggressiveness, tumor plasticity, chemoresistance, metastasis, cell migration and invasion, MDA-MB-231 cells
MeSH terms
Breast Neoplasms, Cell Line, Cell Movement, Female, Humans, Glycosyltransferases, Heparan Sulfate Proteoglycans, Cell Line, Tumor, STAT3 Transcription Factor, Epithelial-Mesenchymal Transition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The exostosin glycosyltransferase 1/STAT3 axis is a driver of breast cancer aggressiveness. https://app.cochat.ai/papers/10.1073/pnas.2316733121
The paper
Solaimuthu, B., Khatib, A., Tanna, M., Karmi, A., Hayashi, A., Abu Rmaileh, A., Lichtenstein, M., Takoe, S., Jolly, M. K., & Shaul, Y. D. (2024). The exostosin glycosyltransferase 1/STAT3 axis is a driver of breast cancer aggressiveness. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2316733121

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.